LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2351

Search options

  1. Book ; Online ; E-Book: New rapid-acting antidepressants

    Hashimoto, Kenji / Manto, Mario

    (Contemporary clinical neuroscience)

    2021  

    Author's details Kenji Hashimoto, Mario Manto editors
    Series title Contemporary clinical neuroscience
    Keywords Neurosciences
    Language English
    Size 1 Online-Ressource (vii, 149 Seiten), Illustrationen, Diagramme
    Publisher Springer
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT021127329
    ISBN 978-3-030-79790-4 ; 9783030797898 ; 3-030-79790-2 ; 3030797899
    DOI 10.1007/978-3-030-79790-4
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book ; Online ; E-Book: The NMDA receptors

    Hashimoto, Kenji

    (The receptors ; 30)

    2017  

    Author's details Kenji Hashimoto editor
    Series title The receptors ; 30
    Collection
    Keywords Receptors, N-Methyl-D-Aspartate / physiology ; Mental Disorders ; Neurodegenerative Diseases
    Language English
    Size 1 Online-Ressource (x, 148 Seiten), Illustrationen, Diagramme
    Publisher Humana Press
    Publishing place Cham
    Publishing country Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019702108
    ISBN 978-3-319-49795-2 ; 9783319497938 ; 3-319-49795-2 ; 3319497936
    DOI 10.1007/978-3-319-49795-2
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  3. Book ; Online: Cognitive Enhancement in Psychiatric Disorders

    Sumiyoshi, Tomiki / Hashimoto, Kenji

    2019  

    Keywords Medicine ; Psychiatry ; Cognition ; Functional outcomes ; Therapeutics ; Assessment ; Biomarkers
    Size 1 electronic resource (261 pages)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021231174
    ISBN 9782889630554 ; 2889630552
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  4. Article ; Online: Beneficial and adverse effects of ketamine and its enantiomers, and the underlying mechanisms of ECT and rTMS efficacy.

    Hashimoto, Kenji

    European archives of psychiatry and clinical neuroscience

    2024  

    Language English
    Publishing date 2024-04-12
    Publishing country Germany
    Document type Editorial
    ZDB-ID 1045583-8
    ISSN 1433-8491 ; 0175-758X ; 0940-1334
    ISSN (online) 1433-8491
    ISSN 0175-758X ; 0940-1334
    DOI 10.1007/s00406-024-01810-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis.

    Hashimoto, Kenji

    Brain, behavior, & immunity - health

    2024  Volume 37, Page(s) 100752

    Abstract: Accumulating evidence suggests that the Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS). Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the ... ...

    Abstract Accumulating evidence suggests that the Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS). Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the endoplasmic reticulum during EBV reactivation, the author proposes that fluvoxamine, an antidepressant with sigma-1 receptor agonism, could be a suitable therapeutic drug for MS.
    Language English
    Publishing date 2024-03-13
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2666-3546
    ISSN (online) 2666-3546
    DOI 10.1016/j.bbih.2024.100752
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?

    Hashimoto, Kenji

    European archives of psychiatry and clinical neuroscience

    2024  

    Abstract: The growing interest in the rapid and sustained antidepressant effects of the dissociative anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However, both ketamine and psychedelics are known to induce acute mystical ... ...

    Abstract The growing interest in the rapid and sustained antidepressant effects of the dissociative anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However, both ketamine and psychedelics are known to induce acute mystical experiences; ketamine can cause dissociative symptoms such as out-of-body experience, while psychedelics typically bring about hallucinogenic experiences, like a profound sense of unity with the universe or nature. The role of these mystical experiences in enhancing the antidepressant outcomes for patients with depression is currently an area of ongoing investigation and debate. Clinical studies have shown that the dissociative symptoms following the administration of ketamine or (S)-ketamine (esketamine) are not directly linked to their antidepressant properties. In contrast, the antidepressant potential of (R)-ketamine (arketamine), thought to lack dissociative side effects, has yet to be conclusively proven in large-scale clinical trials. Moreover, although the activation of the serotonin 5-HT
    Language English
    Publishing date 2024-02-27
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 1045583-8
    ISSN 1433-8491 ; 0175-758X ; 0940-1334
    ISSN (online) 1433-8491
    ISSN 0175-758X ; 0940-1334
    DOI 10.1007/s00406-024-01770-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Online: Glutamate-Related Biomarkers for Neuropsychiatric Disorders

    Lane, Hsien-Yuan / Lin, Chieh-Hsin / Hashimoto, Kenji

    2020  

    Keywords Medicine ; Psychiatry ; glutamate ; NMDA ; schizophrenia ; depression ; Alzheimer's disease ; autoimmune encephalitis ; autism ; addiction
    Size 1 electronic resource (115 pages)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021230596
    ISBN 9782889633791 ; 2889633799
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  8. Book ; Online ; E-Book: Ketamine

    Hashimoto, Kenji / Ide, Soichiro / Ikeda, Kazutaka

    From Abused Drug to Rapid-Acting Antidepressant

    2020  

    Abstract: This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious ... ...

    Author's details edited by Kenji Hashimoto, Soichiro Ide, Kazutaka Ikeda
    Abstract This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants. .
    Keywords Neurosciences ; Pharmacology ; Laboratory medicine ; Neurobiology ; Neuropsychology ; Neurology  ; Pharmacology/Toxicology ; Laboratory Medicine ; Neurology
    Subject code 615.781
    Language English
    Size 1 online resource (V, 189 p. 27 illus., 13 illus. in color.)
    Edition 1st ed. 2020.
    Publisher Springer Singapore ; Imprint: Springer
    Publishing place Singapore
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 981-15-2902-7 ; 981-15-2901-9 ; 978-981-15-2902-3 ; 978-981-15-2901-6
    DOI 10.1007/978-981-15-2902-3
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  9. Article ; Online: Overview of the potential use of fluvoxamine for COVID-19 and long COVID.

    Hashimoto, Kenji

    Discover mental health

    2023  Volume 3, Issue 1, Page(s) 9

    Abstract: Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to public health since its emergence in late 2019. From a safety point of view, drug repurposing has received particular attention. Several clinical studies have demonstrated ... ...

    Abstract Coronavirus disease 2019 (COVID-19) has presented a serious worldwide threat to public health since its emergence in late 2019. From a safety point of view, drug repurposing has received particular attention. Several clinical studies have demonstrated that the use of fluvoxamine, a selective serotonin reuptake inhibitor with potent sigma-1 receptor agonism, in the early-stage of infection might be associated with the prevention of clinical deterioration in individuals with SARS-CoV-2 infection, although several reports have shown that a low dose of fluvoxamine may be ineffective. There is increasing evidence that SARS-CoV-2 can cross the blood-brain barrier, resulting in a number of psychiatric and neurologic symptoms in COVID-19 survivors. Importantly, about half of COVID-19 survivors experience a variety of long-term sequelae, including psychiatric and neurologic symptoms, known as long COVID. In this priority review, the author presents an overview of the potential use of fluvoxamine in the treatment of COVID-19 and long COVID.
    Language English
    Publishing date 2023-03-21
    Publishing country Switzerland
    Document type Journal Article ; Review
    ISSN 2731-4383
    ISSN (online) 2731-4383
    DOI 10.1007/s44192-023-00036-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directions.

    Hashimoto, Kenji

    Molecular psychiatry

    2023  Volume 28, Issue 9, Page(s) 3625–3637

    Abstract: The human body harbors a diverse ecosystem of microorganisms, including bacteria, viruses, and fungi, collectively known as the microbiota. Current research is increasingly focusing on the potential association between the microbiota and various ... ...

    Abstract The human body harbors a diverse ecosystem of microorganisms, including bacteria, viruses, and fungi, collectively known as the microbiota. Current research is increasingly focusing on the potential association between the microbiota and various neuropsychiatric disorders. The microbiota resides in various parts of the body, such as the oral cavity, nasal passages, lungs, gut, skin, bladder, and vagina. The gut microbiota in the gastrointestinal tract has received particular attention due to its high abundance and its potential role in psychiatric and neurodegenerative disorders. However, the microbiota presents in other body tissues, though less abundant, also plays crucial role in immune system and human homeostasis, thus influencing the development and progression of neuropsychiatric disorders. For example, oral microbiota imbalance and associated periodontitis might increase the risk for neuropsychiatric disorders. Additionally, studies using the postmortem brain samples have detected the widespread presence of oral bacteria in the brains of patients with Alzheimer's disease. This article provides an overview of the emerging role of the host microbiota in neuropsychiatric disorders and discusses future directions, such as underlying biological mechanisms, reliable biomarkers associated with the host microbiota, and microbiota-targeted interventions, for research in this field.
    MeSH term(s) Humans ; Microbiota ; Gastrointestinal Microbiome ; Brain ; Alzheimer Disease
    Language English
    Publishing date 2023-10-16
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1330655-8
    ISSN 1476-5578 ; 1359-4184
    ISSN (online) 1476-5578
    ISSN 1359-4184
    DOI 10.1038/s41380-023-02287-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top